Business
DiaSorin S p A : introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN
DiaSorin S p A : introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with
About this update from Diasorin S.p.a.
Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN THE LIAISON QUANTIFERON-TB GOLD PLUS II ASSAY: has received PMA approval from the U.S. Food and Drug Administration and will be available in the United States at the end of March 2026 ENHANCES LABORATORY PRODUCTIVITY AND WORKFLOW EFFICIENCY THROUGH 25% FASTER TURNAROUND TIME COMPARED TO THE PREVIOUS GENERATION ASSAY enables laboratories to test up to 75% more patients per hour, supporting increasing demand for scalable and efficient latent tuberculosis (LTBI) screening workflows Saluggia, Italy - Venlo, the Netherlands - February 24, 2026 - Diasorin (FTSE MIB: DIA) today announces the U.S. FDA approval of the LIAISON QuantiFERON-TB Gold Plus II assay as a next-generation automated Interferon Gamma Release Assay (IGRA) designed in partnership with QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) to enhance laboratory productivity, workflow efficiency and turnaround time for latent tuberculosis infection (LTBI) testing in the United States. The new assay enables laboratories to test up to 75% more patients per hour and achieve a 25% faster turnaround time compared to the previous version. This marks a major advance in workflow efficiency and productivity for TB diagnostics, combining Diasorin's high-throughput LIAISON platforms with QIAGEN's gold-standard QuantiFERON technology - giving laboratories a faster, more efficient solution to meet growing global demand for TB testing. LTBI affects roughly 25% of the world's population, with up to 10% at risk of progressing to active disease if untreated. In the United States, over 80% of tuberculosis (TB) disease cases are estimated to result from reactivation of latent TB infection (LTBI) acquired within the prior two years. Faster, scalable testing is essential to achieving World Health Organization (WHO) targets for TB elimination. The LIAISON QuantiFERON-TB Gold Plus II provides laboratories with a powerful tool to expand screening access and strengthen global TB prevention efforts. "With more than 10 million1 people receiving a ne diagnosis of tuberculosis annually, tuberculosis continues to be a challenge in diagnosis and treatment," said Peter Colaninno, MS, Director of Laboratory Operations, Sunrise Medical Laboratories, Inc. a division of Sonic Healthcare USA. "Because of its high r...